BONESUPPORT™ – Positive clinical data for CERAMENT® G in infection management presented at BLRS 2018
Lund, Sweden, 08.00 CET, 21 March 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that three papers based on the successful use of CERAMENT® G to treat bone infections were presented at the British Limb Reconstruction Society (BLRS) Meeting 2018, which took place from the 15-16th March in Southampton.
One of the papers, entitled ‘The choice of local antibiotic carrier significantly affects outcome in treatment of chronic bone infection’ by J Ferguson, M Mifsud, D Stubbs and MA McNally, compared the use of CERAMENT® G in 160 patients with chronic bone infection (mean follow-up 1.4 years) vs the use of Osteoset® T in 137 patients with chronic bone infection (mean follow-up 2.5 years). The data presented showed that CERAMENT® G demonstrates significantly better bone healing and is associated with a lower rate of recurrent infection, wound leakage and subsequent fracture risk.
A second of the papers was ‘Internal Fixation and Local Antibiotics for Infected Non-unions; technique and outcome at over one year’ by MA McNally, J Ferguson, M Mifsud and D Stubbs. In a series of 12 cases of infected non-union and segmental bone loss up to 1cm treated by intramedullary nails/plates and CERAMENT® G, all patients were infection free at a mean follow-up of 23 months and union was achieved in 92% of patients with primary surgery alone.
The final paper presented was ‘Outcomes of simultaneous Ilizarov frame reconstruction and free muscle flaps in the management of complex limb infection’ by M Mifsud, J Ferguson, D Stubbs, A Ramsden and MA McNally. In a series of 56 patients (34 osteomyelitis and 22 infected non-unions) treated by Ilizarov reconstruction (a type of external fixation), muscle flaps and CERAMENT® G, at a mean follow-up of 22 months, 97.7% had achieved bony union. Recurrence rate of infection in this very challenging subgroup of patients was 8.9%.
Mr Martin McNally, Consultant Bone Infection and Limb Reconstruction Surgeon at Oxford University Hospitals (Oxford, UK) and co-author on all papers presented, said: “The papers we have presented at BLRS continue to emphasise the important benefits that CERAMENT® G can provide in various bone infection situations across large numbers of patients. Its ability to prevent infection recurrence through local antibiotic delivery whilst simultaneously allowing for bone remodelling offers advantages including reduced readmission rates and number of operations for patients.”
BLRS brings together surgeons and associated professionals with the aim of advancing education and research in the field of limb reconstruction.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews
+44 (0)20 7282 1022
bonesupport@citigatedewerogerson.com
About BONESUPPORT™
BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%. The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States
BONESUPPORT™ and CERAMENT® are registered trademarks.